Pacira Pivots: Divesting iovera, Expanding Payer Access, and Stacking Pipeline Catalysts

Divesting to Focus

Pacira BioSciences’ second quarter was defined less by its numbers than by a strategic reshaping. The company completed the divestiture of its iovera business to Zimmer Biomet, collecting up to $140 million ($70 million upfront) while retaining a share of future success via revenue milestones. “completing the iovera divestiture on July 31st, and forming a partnership in spasticity with Zimmer Biomet” — Frank Lee, Chief Executive Officer · 2026-08-04 said CEO Frank Lee. The move crystallizes a transition away from the medtech world toward a leaner, innovation-driven pharmaceutical profile.

That refocus was explicit in the Q&A.

Now we are very clear-minded about being a pharmaceutical company as opposed to being a pharmaceutical and medtech company... this focus will help us execute even better going forward.

Coverage at Scale

Reimbursement momentum remains the core growth story. Pacira announced that UnitedHealthcare, the country’s largest insurer, will now pay for EXPAREL separately from the surgical bundle, pushing total covered lives to more than 150 million—approximately half of the medically insured U.S. population. “We recently secured a major win with UnitedHealthcare, now providing separate reimbursement for EXPAREL outside of the surgical bundle.” — Frank Lee, Chief Executive Officer · 2026-08-04 The win follows a steady campaign: as recently as the company’s fourth-quarter call, management noted 110 million covered lives. “That number has already climbed to about 110,000,000 within 2026” — Brendan P. Teehan, Chief Commercial Officer · 2026-02-26 Brendan Teehan said then. Now the covered lives and separate reimbursement narrative is accelerating, with Commercial payers following United’s lead—a validation of the health-economic data the company has been cultivating.

Catalysts on the Horizon

Beyond access, the pipeline is entering a pivotal window. Management guided to three top-line readouts by year-end: the Phase 2 Part A study of PCRX-201 for knee osteoarthritis, the registrational ZILRETTA shoulder osteoarthritis study, and the iovera spasticity (now partnered with Zimmer) study. Jonathan Slonin reiterated the timeline: “our plan is at the end of the year, we're going to have these three readouts, top-line readouts for Part A.” — Jonathan Slonin, Unknown · 2026-08-04 Earlier this year, he had set expectations for the readout: “the first part of 45 patients... we will have top-line data at the end of the year around safety and trends for our endpoints.” — Jonathan Slonin, Unknown · 2026-02-26 Now, with enrollment in Part B opened, the company is also positioning PCRX 202 as a potential complement to EXPAREL. The registrational study in spasticity was completed, and manufacturing scale-up for PCRX-201 is expected to support a commercially viable product.

Financial Discipline

The revenue picture was muted—total second-quarter revenue of $192.4 million was only 6% above last year, with EXPAREL volume up 4% but offset by vial mix and discounting. Still, the company maintained its full-year guidance for EXPAREL net sales of $600–620 million. Gross margin held at 78% on a non-GAAP basis, and management reiterated its 5x30 strategy of improving operating efficiency. The consolidated non-GAAP gross margin came in at 78% for the quarter, down from 82% a year ago, but still comfortably within the guided 77–79% range. The iovera divestiture should further improve the margin profile by removing a lower-margin medtech business, while strong cash generation and a $251 million cash balance provide ample runway for the pending catalysts.